IP Verse

Pharmaceutical Anti-Tnf-Alpha Antibody Formulation - EP3212667B1

PatentPatent Analysis

EP3212667

RICHTER GEDEON NYRT
Application Number
EP15808356A
Filing Date
Oct 28, 2015
Status
Granted And Under Opposition
Aug 17, 2018
Grant Date
Sep 19, 2018
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3877395B1
EP2925324B1
EP2828396B1

Bibliography

The patent EP3212667B1 was granted to Richter Gedeon Nyrt on Sep 19, 2018 following the initial filing on Oct 28, 2015 under the application number EP15808356A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

SAMSUNG BIOEPIS NLDec 12, 2019INTERVENTION WITHDRAWN
BIOGENJun 19, 2019WITHDRAWN
SAMSUNG BIOEPIS UKJun 19, 2019WITHDRAWN

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents